173 related articles for article (PubMed ID: 35866544)
21. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.
Bachet JB; Laurent-Puig P; Meurisse A; Bouché O; Mas L; Taly V; Cohen R; Gornet JM; Artru P; Louafi S; Thirot-Bidault A; Baumgaertner I; Coriat R; Tougeron D; Lecomte T; Mary F; Aparicio T; Marthey L; Blons H; Vernerey D; Taieb J
Eur J Cancer; 2023 Aug; 189():112934. PubMed ID: 37390800
[TBL] [Abstract][Full Text] [Related]
22. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
23. ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis.
Yekedüz E; Köksoy EB; Akbulut H; Ürün Y; Utkan G
Future Oncol; 2021 Jan; 17(3):349-357. PubMed ID: 33356539
[No Abstract] [Full Text] [Related]
24. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
[TBL] [Abstract][Full Text] [Related]
25. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
26. Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA.
Lyskjær I; Kara N; De Noon S; Davies C; Rocha AM; Strobl AC; Usher I; Gerrand C; Strauss SJ; Schrimpf D; von Deimling A; Beck S; Flanagan AM
Eur J Cancer; 2022 Jun; 168():1-11. PubMed ID: 35421838
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
Tie J; Wang Y; Tomasetti C; Li L; Springer S; Kinde I; Silliman N; Tacey M; Wong HL; Christie M; Kosmider S; Skinner I; Wong R; Steel M; Tran B; Desai J; Jones I; Haydon A; Hayes T; Price TJ; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Sci Transl Med; 2016 Jul; 8(346):346ra92. PubMed ID: 27384348
[TBL] [Abstract][Full Text] [Related]
29. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer.
Hofste LSM; Geerlings MJ; von Rhein D; Rütten H; Westenberg AH; Weiss MM; Gilissen C; Hofste T; van der Post RS; Klarenbeek BR; de Wilt JHW; Ligtenberg MJL;
Eur J Surg Oncol; 2023 Jul; 49(7):1283-1290. PubMed ID: 36740555
[TBL] [Abstract][Full Text] [Related]
32. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
35. Serial Circulating Tumor DNA in Monitoring the Effect of Neoadjuvant and Adjuvant Immunotherapy in Patients With Colon Cancer: Case Series and Review of the Literature.
Qin Q; Yang K; Ma T; Wang H; Yu P; Yuan M; Chen Y; Wang H
J Immunother; 2022 Oct; 45(8):358-362. PubMed ID: 35980372
[TBL] [Abstract][Full Text] [Related]
36. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
Sahin IH; Lin Y; Yothers G; Lucas PC; Deming D; George TJ; Kopetz S; Lieu CH; Dasari A
Oncology (Williston Park); 2022 Oct; 36(10):604-608. PubMed ID: 36260786
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
Cavallone L; Aguilar-Mahecha A; Lafleur J; Brousse S; Aldamry M; Roseshter T; Lan C; Alirezaie N; Bareke E; Majewski J; Ferrario C; Hassan S; Discepola F; Seguin C; Mihalcioiu C; Marcus EA; Robidoux A; Roy JA; Pelmus M; Basik M
Sci Rep; 2020 Sep; 10(1):14704. PubMed ID: 32895401
[TBL] [Abstract][Full Text] [Related]
38. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Huerta M; Roselló S; Zuniga S; Calon A; Carbonell-Asins JA; Fontana E; Martinez-Ciarpaglini C; Eason K; Rentero-Garrido P; Fleitas T; Papaccio F; Moro-Valdezate D; Nyamundanda G; Castillo J; Espí A; Sadanandam A; Roda D; Cervantes A
ESMO Open; 2020 Sep; 5(5):e000847. PubMed ID: 32967918
[TBL] [Abstract][Full Text] [Related]
39. Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials.
Conca V; Ciracì P; Boccaccio C; Minelli A; Antoniotti C; Cremolini C
Cancer Treat Rev; 2024 May; 126():102735. PubMed ID: 38613871
[TBL] [Abstract][Full Text] [Related]
40. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma.
Azzi G; Tavallai M; Aushev VN; Koyen Malashevich A; Botta GP; Tejani MA; Hanna D; Krinshpun S; Malhotra M; Jurdi A; Aleshin A; Kasi PM
Oncologist; 2023 Mar; 28(3):220-229. PubMed ID: 36562592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
